Less Ads, More Data, More Tools Register for FREE

Pin to quick picksApax Global Alpha Regulatory News (APAX)

  • This share is currently suspended. It was suspended at a price of 164.40
  • There is currently no data for APAX

Form 8.3 - APAX LN

14 Aug 2025 15:30

RNS Number : 3582V
Syquant Capital
14 August 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

SYQUANT CAPITAL

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Apax Global Alpha Limited

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

August 13, 2025

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary NPV

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

4,412,253

0.91%

 

 

(2) Derivatives (other than options):

836,450

0.17%

 

(3) Options and agreements to purchase/sell:

 

 

 

 

TOTAL:

5,248,703

1.08%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Ordinary NPV

 

CFD

 

increasing a long position

 

2,800,000

 

162.6 GBp

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

N/A

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

August 14, 2025

Contact name:

Laurent Boscherel

Telephone number:

+33 1 42 56 56 27

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETSFUSULEISEEA
Date   Source Headline
2nd Mar 20237:00 amRNS2022 Final Results
2nd Feb 20237:00 amRNSThe Apax Digital Fund II invests in Magaya
2nd Feb 20237:00 amRNSApax Funds’ Valuations and Credit Facility update
24th Jan 202310:15 amEQSHardman & Co Q&A on Apax Global Alpha (APAX): Adding value to private companies
13th Jan 202311:10 amEQSHardman & Co Research on Apax Global Alpha (Initiation of coverage): Making pearls out of oysters
13th Jan 20237:00 amRNSDuck Creek Technologies to be acquired by Vista
10th Nov 20227:00 amRNSApax IX sells stake in Kepro
4th Nov 20227:00 amRNSQuarterly Results for 30 September 2022
22nd Sep 20227:00 amRNSApax IX agrees to sell stake in Authority Brands
14th Sep 20227:00 amRNSThe Apax Digital Fund II invests in Xeneta
19th Aug 20227:00 amRNS2022 Interim Dividend
19th Aug 20227:00 amRNS2022 Interim Report and Accounts
19th Aug 20227:00 amRNS2022 Interim Results Highlights
5th Aug 20227:00 amRNSApax Funds’ Valuations as at 30 June 2022
26th Jul 20227:00 amRNSFunds advised by Apax to acquire Pickles Auctions
29th Jun 20227:00 amRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSProposed commitment to Apax XI
17th Jun 20227:00 amRNSDirector Declaration - Additional Directorship
10th Jun 20227:00 amRNSFunds Advised by Apax Sell Stake in MyCase
7th Jun 20227:00 amRNSFunds advised by Apax to acquire EcoOnline
13th May 20224:02 pmRNSDirector/PDMR Shareholding
12th May 20227:00 amRNSDirector/PDMR Shareholding
6th May 20227:00 amRNSResult of AGM
6th May 20227:00 amRNSIncrease to the Revolving Credit Facility
6th May 20227:00 amRNSQuarterly results for 31 March 2022
7th Apr 20227:00 amRNSProposed commitment to AMI Opportunities Fund II
22nd Mar 20227:00 amRNSApax Digital Funds invest in ClearBank
17th Mar 20223:59 pmRNSPurchase of Ordinary Shares under IM Agreement
8th Mar 20227:00 amRNSProposed commitment to Apax Global Impact Fund
2nd Mar 20227:00 amRNSKey Information Document
2nd Mar 20227:00 amRNS2021 Annual Dividend Declaration
2nd Mar 20227:00 amRNSNotice of AGM
2nd Mar 20227:00 amRNS2021 Annual Report and Accounts
2nd Mar 20227:00 amRNS2021 Final Results
14th Feb 20227:00 amRNSApax X invests in Alcumus and Ole Smoky
3rd Feb 20227:00 amRNSApax Funds’ Valuations as at 31 December 2021
31st Jan 20224:36 pmRNSPrice Monitoring Extension
23rd Dec 202110:30 amRNSDirector Declaration
17th Dec 20219:30 amRNSDirector Declaration
6th Dec 20217:00 amRNSFunds advised by Apax sell stakes in Unilabs
9th Nov 20217:00 amRNSInmarsat agrees combination with Viasat
4th Nov 20217:00 amRNSQuarterly results for 30 September 2021
2nd Nov 20217:00 amRNSFunds advised by Apax announce investment in Lever
1st Nov 20217:00 amRNSApax Funds to acquire HSG
6th Oct 20217:00 amRNSApax Funds to acquire Eating Recovery Center
16th Sep 20217:00 amRNSInitial Public Offering of Thoughtworks
8th Sep 20217:00 amRNSFunds advised by Apax to invest in T-Mobile
2nd Sep 20217:00 amRNSWizeline Acquired by CDPQ
1st Sep 20217:00 amRNSFunds advised by Apax to acquire SavATree
31st Aug 20215:40 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.